Medifast's Q4 Guidance Falls Short, Long-Term Growth Expected with Metabolic Health Focus

Medifast's Q4 guidance is weak, with revenue projected between $65 million and $80 million and a loss per share of 70-125 cents. The company is transitioning from a weight loss company to a metabolic health leader, with a new product line launching next year. Revenue per active coach is expected to improve as early as Q4, with overall revenue growth following within 1-2 quarters. MED trades at a forward price-to-sales ratio of 0.37, lower than the industry average of 1.10.